Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNF α receptors

L Berg*, J Lampa*, S Rogberg, R van Vollenhoven, L Klareskog

Abstract

Objective—Peripheral T cells from patients with rheumatoid arthritis (RA) are hyporesponsive when stimulated with antigen or mitogen in vitro, possibly owing to increased production of proinflammatory cytokines such as tumour necrosis factor α (TNF α). This study sought to find out if and how RA T cell reactivity is affected during treatment with etanercept (Enbrel), a soluble TNF α receptor.

Methods—Heparinised blood was collected from patients with RA at baseline, after four and eight weeks of etanercept treatment, and from healthy controls. After density separation spontaneous production of interferon γ (IFN γ), TNF α , interleukin 6 (IL6), and IL10 by peripheral blood mononuclear cells (PBMC) was detected by ELISPOT. For detection of T cell reactivity, PBMC were stimulated in vitro with mitogen (phytohaemagglutinin (PHA)), microbial antigens (purified protein derivative (PPD), influenza), or an autoantigen, collagen type II (CII). Supernatants were analysed for IFN γ and IL2 content by enzyme linked immunosorbent assay (ELISA).

Results—In RA the number of cells spontaneously producing IFN γ was significantly increased after four, but not eight weeks' treatment with etanercept. T cell reactivity, as measured by IFN γ production to PPD, influenza, and CII was significantly increased after four and sustained after eight weeks' treatment, whereas IFN γ production induced by PHA remained unchanged. TNF α production was significantly higher in patients with RA than in controls and did not change during etanercept treatment.

Conclusion—Treatment of patients with RA with etanercept may lead to increased peripheral T cell reactivity both to microbial antigens and to self antigens such as CII. These findings indicate that TNF α blockade may not only suppress but also stimulate certain aspects of antimicrobial immune defence and autoimmunity.

(Ann Rheum Dis 2001;60:133–139)

Treatment with agents blocking the function of tumour necrosis factor α (TNF α) has proved to be highly effective in ameliorating the symptoms of chronic joint inflammation characteris-

tic of rheumatoid arthritis (RA).^{1,2} To date, there are two TNF α blocking agents in clinical use, a monoclonal antibody (infliximab) and a soluble TNF α receptor (etanercept). The mechanisms behind the clinical effect of the TNF α blocking treatment are not fully understood, but both a reduced influx of inflammatory cells into the joints owing to downregulation of synovial endothelial adhesiveness^{3,4} and a direct interruption of the cytokine cascade driving the inflammatory process⁵ have been seen.

The association of RA with certain major histocompatibility complex class II genotypes has indicated that T cells are of importance in the pathogenesis. However, T cells obtained from either the circulation or from the synovial fluid of patients with RA are hyporesponsive when stimulated in vitro with antigen or mitogen compared with T cells from the blood of healthy controls.^{6–11} Earlier studies have shown that activated monocytes/macrophages suppress T cell functions, and this may be effected through the action of proinflammatory cytokines such as TNF α . Thus besides being an effector cytokine in the immune system, TNF α may also have immune modulating properties, something that has also been shown in animal studies.¹² Several studies have indicated that TNF α blockade with infliximab increases T cell reactivity.^{13,14} However, the influence of etanercept treatment has not been studied in this respect and there is also limited knowledge of how TNF α blockade influences immune reactivity against specific microbial agents or autoantigens. Against this background we wanted to investigate peripheral blood cytokine production and T cell reactivity to purified protein derivative (PPD), influenza virus, and the autoantigen collagen type II (CII) in patients with RA during etanercept treatment.

Methods

PATIENTS AND HEALTHY CONTROLS

Seventeen patients fulfilling the American College of Rheumatism (ACR) criteria for RA¹⁵ were recruited (12 women, five men, median age 48, range 31–69). Each patient had a history of unsuccessful treatment with at least one disease modifying antirheumatic drug (DMARD). The median disease duration was 132 months (range 24–324). Twelve patients (71%) were rheumatoid factor positive, 11 (65%) were treated with methotrexate. One patient received a combination of auranofin

Department of Medicine, Unit of Rheumatology, Karolinska Institute, Stockholm, Sweden

L Berg
J Lampa
S Rogberg
R van Vollenhoven
L Klareskog

Correspondence to:
Drs L Berg and J Lampa,
Department of Medicine,
Unit of Rheumatology,
Karolinska Hospital, CMM
L8:04, 171 76 Stockholm,
Sweden
louise.berg@cmm.ki.se
jon.lampa@divmed.ks.se

Accepted 28 June 2000

*Contributed equally.

Figure 1 The number of cells spontaneously producing interferon γ (IFN γ) increases after four weeks of treatment with etanercept. The number of IFN γ producing cells/100 000 unstimulated peripheral blood mononuclear cells (PBMC) was enumerated by the ELISPOT method. PBMC from healthy controls (HC, n=17) or patients with RA (n=17) were analysed at baseline and after four and eight weeks of treatment.

and methotrexate, another methotrexate and sulfasalazine, and one patient sulfasalazine alone. Twelve patients received prednisolone, either alone (n=4) or in combination with the DMARDs mentioned (n=8). In five patients auranofin, hydroxychloroquine, cyclosporin A in combination with mykophenolatmophetil (CellCept), sulfasalazine resp CPH-82 (Reumacron) were washed out two weeks before the start of etanercept treatment. No patient was treated with more than 10 mg prednisolone daily. Initially, the median C reactive protein was 34 mg/l (range 10–166).

Patients were treated with subcutaneous injections of 25 mg etanercept (Wyeth-Ayerst¹⁶) twice every week. Heparinised blood was collected before the start of treatment and after four and eight weeks of treatment. Healthy controls of similar age and sex as the patients with RA (median age 50, range 40–58, 12 female, five male) were recruited from the rheumatology laboratory and clinic at Karolinska Hospital.

EVALUATION OF CLINICAL RESPONSE

The clinical response of the treatment was measured in accordance with the ACR response criteria,¹⁷ using the 28 joint count.

CELL SEPARATION

Peripheral blood was collected in heparinised tubes and diluted 1:2 with phosphate buffered saline. Mononuclear cells were isolated by density gradient centrifugation and diluted to 1×10^6 cells/ml in RPMI 1640 (Flow laboratories, Irvine, Scotland, UK) supplemented with glutamine, HEPES buffer, penicillin, streptomycin, and 10% of a defined batch of fetal calf serum (FCS) (Flow). These cells were then used without further stimulation for the enumeration of cytokine producing cells and for antigen and mitogen stimulation.

ELISPOT ANALYSIS OF NUMBER OF CYTOKINE PRODUCING PERIPHERAL BLOOD MONONUCLEAR CELLS

ELISA plates were coated with primary antibody, 50 μ l/well, 15 μ g/ml overnight at 4°C. Cells were added (10^5 cells/well for interferon γ (IFN γ), 2.5×10^4 /well for interleukin 10 (IL10), 2000/well for IL6, and 500/well for TNF α) in RPMI-10% FCS and incubated overnight. Wells were washed and a biotinylated antibody was added at 1 μ g/ml overnight. Avidine-alkaline phosphatase (Dakopatts) was added at a dilution of 1:250 and allowed to bind for two hours, and 5-bromo-4-chloro-3-indolyl phosphate, 2.3 mM (Sigma) was added after washing to develop the ELISPOT for five hours. The number of cytokine producing cells was counted with an inverted-beam microscope. Antibodies used were 1-D1K (MabTech) and biotinylated 7-B6-1 (MabTech) for IFN γ , 19F1 (Pharmingen) and biotinylated 12G8 (American Type Culture Collection (ATCC), Manassas, VA, USA) for IL10, 13A5 (Pharmingen) and biotinylated 39C3 (Pharmingen) for IL6, and 20-A4 (ATCC) and biotinylated secondary antibody derived from Genzyme's Duokit for TNF α .

ANTIGEN AND MITOGEN STIMULATION OF PBMC

Antigen or mitogen (PPD 10 μ g/ml (Statens Smittskyddsinstitut, Solna, Sweden), killed whole influenza virus diluted 1:1000 (Vaxigrip, Pasteur Mérieux, Lyon, France), chick CII 100 μ g/ml (Sigma, St Louis, MO, USA), or phytohaemagglutinin (PHA) 5 μ g/ml (Statens Smittskyddsinstitut)) were added to 1 ml of the cell suspension. Cells were incubated in round bottomed, 96 well plates (NUNC A/S, Roskilde, Denmark) and supernatants were collected and frozen after three days for the analyses of IL2 and PHA induced IFN γ and after seven days for the analyses of antigen induced IFN γ . The kinetics of cytokine production were analysed in pilot studies and found to correspond to a previous publication.¹⁸

CYTOKINE MEASUREMENTS IN SUPERNATANTS USING ELISA

Supernatants were analysed for cytokine content by ELISA using paired antibodies for

Figure 3 *In vitro* mitogen reactivity was increased after treatment with etanercept. Peripheral blood mononuclear cells were separated from the blood of healthy controls (HC, $n=17$) or patients with RA ($n=17$) at baseline and after four and eight weeks of treatment and incubated with phytohaemagglutinin ($5 \mu\text{g/ml}$). Supernatants were collected after three days for the analysis of interferon γ (IFN γ) (A) and interleukin 2 (IL2) (B) using ELISA. Levels of cytokine obtained after incubation without further stimulation were subtracted.

IFN γ analysis (1-D1K as primary antibody and 7-B6-1 as biotinylated secondary antibody, MabTech, Stockholm, Sweden) as described earlier.⁶ For IL2 analysis, a commercial Duokit was used (R&D Systems, Minneapolis, MN, USA), as recommended by the manufacturer.

STATISTICAL ANALYSIS

Non-parametric methods were used throughout the report. Differences between groups were analysed with the Mann-Whitney U test, and analyses for matched pairs were performed with Wilcoxon's signed rank test. $p < 0.05$ was considered significant.

Results

NUMBER OF CELLS SPONTANEOUSLY PRODUCING CYTOKINES IN PERIPHERAL BLOOD MONONUCLEAR CELLS

The number of cells producing IFN γ , IL10, IL6, and TNF α without further stimulation was determined by the ELISPOT method. All numbers given represent the number of cytokine producing cells/100 000 peripheral blood mononuclear cells (PBMC) as median and range. After four weeks of treatment with etanercept, a clear increase in the number of cells spontaneously producing IFN γ was re-

corded (fig 1). However, this effect was transient, as no difference between the number of cells producing IFN γ at baseline and after eight weeks of treatment was recorded. No difference in the number of IFN γ producing cells was seen between controls and patients with RA before etanercept treatment (fig 1).

We detected a significantly increased number of TNF α producing cells in patients with RA at baseline (15 400 (range 6600–48 800)) compared with controls (12 000 (range 6800–22 000), $p=0.04$). However, etanercept treatment had no effect on the number of TNF α producing PBMC (data not shown).

There were no differences in IL10 and IL6 production between controls and patients with RA at baseline (data not shown). Etanercept treatment had no effect on the numbers of IL6 and IL10 producing cells (data not shown).

ANTIGEN REACTIVITY AFTER ETANERCEPT TREATMENT

A marked T cell hyporesponsiveness to microbe derived recall antigens was seen in patients with RA as compared with controls.^{6–10} This was evident for PPD induced IFN γ (fig 2A) and influenza induced IFN γ (fig 2C), as

well as for influenza induced IL2 73 pg/ml (12–200) for controls *v* 46 pg/ml (11–171) for RA, $p=0.02$, figure not shown).

After four weeks of etanercept treatment, PPD-induced in vitro production of IFN γ (fig 2A) and IL2 (fig 2B), and influenza-induced in vitro production of IFN γ (fig 2C) increased compared with baseline. After eight weeks of etanercept treatment, IFN γ responses, but not IL2 responses, showed a sustained increase compared with baseline.

Upon stimulation with CII, a cartilage derived antigen, no difference in the production of IFN γ could be detected between patients with RA and controls (fig 2D), confirming earlier published results from our laboratory⁶ and pointing towards a lack of T cell hyporesponsiveness to the autoantigen CII in patients with RA. The IFN γ response to CII stimulation increased after both four and eight weeks of treatment with etanercept compared with baseline (fig 2D).

MITOGEN REACTIVITY AFTER ETANERCEPT TREATMENT

PHA stimulation of control PBMC resulted in a significantly higher IFN γ response than that of RA PBMC at baseline (fig 3A), but we detected no difference between controls and RA in IL2 response to PHA stimulation (fig 3B). IFN γ production induced by PHA was not affected by etanercept treatment (fig 3A). However, the IL2 response to PHA stimulation was significantly increased after both four and eight weeks of treatment compared with baseline (fig 3B).

CLINICAL RESPONSE

The clinical response to etanercept was in agreement with an earlier description from controlled clinical trials.^{19–20} Thus 13 of the 17 patients (76%) fulfilled the ACR 20 criteria, seven patients (41%) also met the ACR 50 criteria, and one fulfilled ACR 70. Four of the 17 patients (24%) did not fulfil the ACR 20 response criteria.

No association was detected between response to treatment and any of the T cell functional variables measured. Neither could we distinguish any difference in T cell activity between the patients treated with methotrexate and the rest of the patient group. To investigate whether changes of drugs during the study period influenced the results, a subgroup analysis was made on patients that had stable drug treatment throughout the study. The results for IFN γ production and T cell reactivity were confirmed also in this subgroup (data not shown).

Discussion

This is the first report on functional studies of T cells from patients with RA treated with etanercept and we demonstrate an increase in peripheral T cell functions after treatment with the soluble TNF α receptor. This increase in T cell function was measured both as an increase in production of IFN γ of unstimulated PBMC and as an increase in production of IFN γ and

IL2 after stimulation with microbial antigens (PPD or influenza) or autoantigen (CII) in vitro.

We chose to measure T cell activity using two different approaches. Firstly, we analysed IFN γ production *ex vivo* without further stimulation using the highly sensitive ELISPOT technique. We believe that this technique mirrors the cytokine production in vivo more accurately than other methods in which mitogenic stimulation is necessary for the enumeration of cytokine producing cells. Secondly, we determined the capacity for antigenic and mitogenic induction of IFN γ and IL2 by analysing cytokine secretion in cell culture supernatants using ELISA. We chose to study the microbial recall antigens PPD and influenza, as well as the cartilage derived antigen, CII. We also studied mitogen reactivity using PHA. Interestingly, we noted an increased general in vivo production of IFN γ and an increased in vitro responsiveness to both microbial antigens and to CII after treatment with etanercept. The in vitro data on reactivity to certain microbial antigens concord well with those published earlier on peripheral T cell function after treatment with infliximab.^{13–14} These types of data have not previously been documented after etanercept treatment, however, and data have also been lacking on whether TNF α blockade might enhance T cell reactivity to disease associated autoantigens like CII.

One mechanism by which TNF α blocking treatment might increase peripheral T cell function is by interfering with the TNF α dependent activation of monocytes. It is known that T cells from patients with RA can be functionally hyporesponsive^{9–11–21} as a result of the disease itself and irrespective of immunosuppressive drugs,¹⁰ possibly owing to the presence of activated monocytes during active inflammation. Activated monocytes suppress T cell functions by production of TNF α ,^{13–22–23} prostaglandins,²⁴ and hydrogen peroxide.²⁵ Our determination of an increased production of TNF α in RA PBMC is in concordance with reports of a higher activation state of peripheral monocytes in RA than controls.^{26–28} These data support the notion of a monocyte induced and TNF α dependent downregulation of T cell functions in RA. By blocking the action of TNF α in vivo, it is conceivable that the activation of peripheral monocytes is decreased, as indicated by a decrease in serum levels of TNF α , IL1 receptor antagonist, IL6, and soluble TNF α receptor.²⁹ This deactivation of peripheral monocytes might thereby result in an enhanced activation and reactivity of peripheral T cells.

Another possible mechanism behind the increased peripheral T cell reactivity noted after TNF α blocking treatment might be an increase in the number of circulating lymphocytes.^{5–14} This could be due to a decrease in ICAM-1 expression in synovial endothelial cells,^{3–4} which might reduce the extravasation of activated peripheral T cells. A decrease in locally produced TNF α might also affect cellular infiltration of the joint owing to the chemotactic property of TNF α .³⁰ An increase of

peripheral T cells with an activated phenotype,¹⁴ resembling T cells normally present in the joint of patients with RA, further supports the idea of a change in T cell trafficking in patients treated with TNF α blocking agents. As inflammation is suppressed during treatment, the frequency of activated T cells declines, indicated by the reduced number of IFN γ producing cells in the peripheral blood at week 8. No difference in etanercept induced T cell activity was detected between patients responding to treatment and those without clinical response. This could be explained by individual differences in the cytokine regulation.³¹

Patients with RA have an increased mortality due to infections than healthy controls.³² The reason for this increased risk of infection may be the dysregulation of the immune system in RA, which suppresses the function of T cells. Immunosuppressive drugs used to control the disease have also been associated with a risk of infection.^{33,34} Although one might expect an even higher risk of infection when blocking TNF α , a cytokine of pivotal importance in protection against infectious agents, there is presently little published evidence supporting the increased presence of infections in patients with RA treated with etanercept.^{19,35} The findings of an increased T cell reactivity to recall microbial antigens after etanercept treatment may partly explain this paradox.

It has been postulated from several studies of experimental autoimmune diseases, such as lupus, experimental autoimmune encephalomyelitis, and diabetes, that blockade of TNF α might lead to exacerbation of disease under certain circumstances.^{12,36,37} To date, there is only one such report in multiple sclerosis that this theoretical concern may be of clinical significance,³⁸ and results from clinical trials in RA using etanercept and infliximab have hitherto not corroborated that risk. However, there have been reports of the appearance of increased autoantibody production after infliximab treatment.^{2,39,40} It is thus interesting to note the increased T cell reactivity to CII in some of the patients treated with etanercept in this study. Although we do not know the exact clinical significance of this anti-CII T cell reactivity, our data suggest that increased reactivity of potential, disease inducing T cells may indeed also occur in patients treated with etanercept.

In conclusion, our data corroborate the notion that TNF α blockade may have stimulating effects on T cell reactivity against microbial agents, thereby possibly compensating for conceivable suppression of infection defence during TNF α blocking treatment. On the other hand, the stimulation of anti-self reactions in our study further emphasises the need for close supervision of patients receiving TNF α blockade so that potential unwanted effects of this new therapeutic principle may be recognised rapidly.

The work was supported by grants from the Swedish Medical Research Council and the Swedish Association against Rheumatism. We thank Associate Professor Robert A Harris for linguistic advice.

- Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. *J Rheumatol* 1999;26:7-15.
- Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. *Lancet* 1994;344:1105-10.
- Tak PP, Taylor PC, Breedveld FC, Smeets TJ, Daha MR, Kluin PM, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. *Arthritis Rheum* 1996;39:1077-81.
- Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. *Arthritis Rheum* 1996;39:1082-91.
- Feldmann M. What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis? *Int Arch Allergy Immunol* 1996;111:362-5.
- Berg L, Ronnelid J, Sanjeevi CB, Lampa J, Klareskog L. Interferon- γ production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1*0401 and HLA-DQ8. *Arthritis Research* 2000;2:75-84.
- Berg L, Ronnelid J, Klareskog L, Bucht A. Down-regulation of the T cell receptor CD3 ζ chain in rheumatoid arthritis (RA) and its influence on T cell responsiveness. *Clin Exp Immunol* 2000;120:174-82.
- Maurice MM, Lankester AC, Bezemer AC, Geertsma MF, Tak PP, Breedveld FC, et al. Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. *J Immunol* 1997;159:2973-8.
- Silverman HA, Johnson JS, Vaughan JH, McGlamory JC. Altered lymphocyte reactivity in rheumatoid arthritis. *Arthritis Rheum* 1976;19:509-15.
- Emery P, Panayi GS, Nouri AM. Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis. *Clin Exp Immunol* 1984;57:123-9.
- Verwilghen J, Vertessen S, Stevens EA, Dequeker J, Ceuppens JL. Depressed T-cell reactivity to recall antigens in rheumatoid arthritis. *J Clin Immunol* 1990;10:90-8.
- Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. *Nature* 1988;331:356-8.
- Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. *J Clin Invest* 1994;94:749-60.
- Maurice MM, van der Graaff WL, Leow A, Breedveld FC, van Lier RA, Verweij CL. Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis. *Arthritis Rheum* 1999;42:2166-73.
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
- Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremmel KE, Fung VP, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. *J Immunol* 1993;151:1548-61.
- Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum* 1993;36:729-40.
- McHugh S, Deighton J, Rifkin I, Ewan P. Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary culture. *Eur J Immunol* 1996;26:1260-5.
- Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. *N Engl J Med* 1997;337:141-7.
- Weinblatt ME, Lange M, Burge DJ. Long-term safety and efficacy of combination therapy with methotrexate (MTX) and etanercept (Enbrel®) [abstract]. *Arthritis Rheum* 1999;42:S401.
- Allen ME, Young SP, Michell RH, Bacon PA. Altered T lymphocyte signaling in rheumatoid arthritis. *Eur J Immunol* 1995;25:1547-54.
- Lai NS, Lan JL, Yu CL, Lin RH. Role of tumor necrosis factor-alpha in the regulation of activated synovial T cell growth: down-regulation of synovial T cells in rheumatoid arthritis patients. *Eur J Immunol* 1995;25:3243-8.
- Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. *J Exp Med* 1997;185:1573-84.
- Vercammen C, Ceuppens JL. Prostaglandin E2 inhibits human T-cell proliferation after crosslinking of the CD3-Ti complex by directly affecting T cells at an early step of the activation process. *Cell Immunol* 1987;104:24-36.
- Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. *Eur J Immunol* 1996;26:1308-13.

- 26 Higaki M, Miyasaka N, Sato K. Increased expression of CD11b (Mo1) on peripheral blood monocytes of patients with rheumatoid arthritis. *J Rheumatol* 1992;19:825–6.
- 27 Shinohara S, Hirohata S, Inoue T, Ito K. Phenotypic analysis of peripheral blood monocytes isolated from patients with rheumatoid arthritis. *J Rheumatol* 1992;19:211–15.
- 28 Torsteinsdottir I, Arvidson NG, Hallgren R, Hakansson L. Monocyte activation in rheumatoid arthritis (RA): increased integrin, Fc gamma and complement receptor expression and the effect of glucocorticoids. *Clin Exp Immunol* 1999;115:554–60.
- 29 Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, *et al*. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF- α therapy in rheumatoid arthritis. *J Immunol* 1999;163:1521–8.
- 30 Taylor PC, Peters AM, Paleolog E, Chapman PT, Elliott MJ, McCloskey R, *et al*. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis. *Arthritis Rheum* 2000;43:38–47.
- 31 Ulfgren AK, Grondal L, Lindblad S, Khademi M, Johnell O, Klareskog L, *et al*. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. *Ann Rheum Dis* 2000;59:439–47.
- 32 Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. *Arthritis Rheum* 1986;29:706–14.
- 33 Hernandez-Cruz B, Cardiel MH, Villa AR, Alcocer-Varela J. Development, recurrence, and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. *J Rheumatol* 1998;25:1900–7.
- 34 van der Veen MJ, van der Heide A, Kruize AA, Bijlsma JW. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. *Ann Rheum Dis* 1994;53:224–8.
- 35 Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, *et al*. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* 1999;340:253–9.
- 36 Rood MJ, van Krugten MV, Zanelli E, van der Linden MW, Keijsers V, Schreuder GM, *et al*. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. *Arthritis Rheum* 2000;43:129–34.
- 37 Jacob CO, Fronck Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor α : relevance to genetic predisposition to systemic lupus erythematosus. *Proc Natl Acad Sci USA* 1990;87:1233–7.
- 38 van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, *et al*. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. *Neurology* 1996;47:1531–4.
- 39 Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, *et al*. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α . *Arthritis Rheum* 1993;36:1681–90.
- 40 Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, *et al*. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet* 1999;354:1932–9.